THERAPY DOSSIER · th-6d1a17ed051f

Nerve growth factor (NGF)

Biologic

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: TBI
Reported indication: Not recorded
First approval: Not recorded
Development stage: In trials, not approved
ChEMBL record: CHEMBL4297796 ↗
ChEMBL max phase: 2 / 4 (development scale, not regulatory approval)
Synonyms: Beta-nerve growth factor; beta-NGF; Human nerve growth factor; Nerve growth hormone; Rh-polypeptide-14
Note: Not recorded

Clinical trials 2

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT03982368 ↗PHASE2completed

rhNGF Eye Drops vs Vehicle in Moderate-Severe Dry Eye

Dry Eye Syndrome

Enrolment: 261 · Results not recorded

NCT04552730 ↗NAcompleted

Cenegermin-bkbj (rhNGF) in Limbal Stem Cell Deficiency / Neurotrophic Keratopathy

Neurotrophic Keratitis

Enrolment: 5 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 3396647 ↗1988Reported benefit

Delayed treatment with nerve growth factor reverses the apparent loss of cholinergic neurons after acute brain damage.

RatTBIUnspecifiedIntraventricularDelayed treatment started 1, 2 and 3 weeks after injury, once most neurons were…

Model: Axotomy of septal cholinergic neurons by acute brain damage (fimbria-fornix type lesion)

NGF started 1, 2 or 3 weeks after axotomy caused a marked reappearance of apparently lost septal cholinergic neurons, indicating the loss reflects reduced detectability of neurotransmitter enzyme rather than neuronal death.

Extraction: extract · Supplied extraction confidence: 0.7. Machine-extracted fields require source verification.

Loading the evidence…